Vyne Therapeutics Inc (NASDAQ:VYNE)
| 3.10 BATS BZX Real-Time Price As of 9:53am ET |  +0.08 / +2.65%Today’s Change | 1.99 Today|||52-Week Range 14.22 | +14.81% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Quarter Trend | |||||
|---|---|---|---|---|---|---|
| Quarter 3 2018 | Quarter 4 2018 | Quarter 1 2019 | Quarter 2 2019 | |||
| Operating Activities | Net Income / Starting Line | -12.8M | -17.6M | -18.9M | -16.5M | |
| Depreciation | 4.0K | 12.0K | 191.0K | 166.0K | ||
| Total Other Cash Flow | 764.0K | 851.0K | 779.0K | 878.0K | ||
| Funds From Operations | -12.1M | -16.7M | -17.9M | -15.4M | ||
| Funds From/For Other Operating Expenses | 93.0K | -113.0K | 161.0K | -1.2M | ||
| Net Cash Flow - Operating Activities | -12.2M | -16.6M | -18.1M | -14.2M | ||
| Investing | Increase In Investments | -26.6M | -16.7M | -21.4M | -13.5M | |
| Decrease In Investments | 35.0M | 12.7M | 48.9M | 29.0M | ||
| Capital Expenditures | -118.0K | -22.0K | -11.0K | 1.0K | ||
| Net Cash Flow Investing | 8.3M | -4.1M | 27.5M | 15.4M | ||
| Financing | Short Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Long Term Debt Reduction | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Net Proceeds Stock Sale | 488.0K | 2.0K | 3.0M | 1.9M | ||
| Common Preferred Redeemed | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Dividends | -- | -- | -- | -- | -- | |
| Cash Dividends Paid - Total | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Sources - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Uses - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Net Cash Flow - Financing | 488.0K | 2.0K | 3.0M | 1.9M | ||
| Exchange Rate | Effect of Exchange Rate on Cash | -- | -- | -- | -- | -- |
| Net Change In Cash | -3.4M | -20.7M | 12.4M | 3.1M | ||
